The pentavalent antimonial therapy against experimental Leishmania amazonensis infection is more effective under the inhibition of the NF-kB pathway

Detalhes bibliográficos
Autor(a) principal: Macedo, Sharon Rose Aragão
Data de Publicação: 2015
Outros Autores: Nicolete, Larissa Deadame de Figueiredo, Ferreira, Amália dos Santos, Barros, Neuza Biguinati de, Nicolete, Roberto
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da FIOCRUZ (ARCA)
Texto Completo: https://www.arca.fiocruz.br/handle/icict/12621
Resumo: 2016-11-30
id CRUZ_612e8f36ca7d75ef79f5b62de14a859f
oai_identifier_str oai:www.arca.fiocruz.br:icict/12621
network_acronym_str CRUZ
network_name_str Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str 2135
spelling Macedo, Sharon Rose AragãoNicolete, Larissa Deadame de FigueiredoFerreira, Amália dos SantosBarros, Neuza Biguinati deNicolete, Roberto2016-01-26T14:37:54Z2015NICOLETE, R. et al. The pentavalent antimonial therapy against experimental Leishmania amazonensis infection is more effective under the inhibition of the NF-κB pathway. International Immunopharmacology (Print), v. 28, p. 554-559, 2015.https://www.arca.fiocruz.br/handle/icict/1262110.1016/j.intimp.2015.07.020engELSEVIERThe pentavalent antimonial therapy against experimental Leishmania amazonensis infection is more effective under the inhibition of the NF-kB pathwayinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article2016-11-30Fundação Oswaldo Cruz. Laboratório de Biotecnologia Aplicada à Saúde. Porto Velho, RO, Brazil. / Universidade Federal de Rondônia. Programa de Pós-Graduação em Biologia Experimental. Porto Velho, RO, Brazil.Fundação Oswaldo Cruz. Laboratório de Biotecnologia Aplicada à Saúde. Porto Velho, RO, Brazil. / Universidade Federal de Rondônia. Programa de Pós-Graduação em Biologia Experimental. Porto Velho, RO, Brazil.Fundação Oswaldo Cruz. Laboratório de Biotecnologia Aplicada à Saúde. Porto Velho, RO, Brazil.Fundação Oswaldo Cruz. Laboratório de Biotecnologia Aplicada à Saúde. Porto Velho, RO, Brazil. / Programa de Pós-Graduação em Biodiversidade e Biotecnologia da Amazônia Legal. Porto Velho, RO, Brazil.Fundação Oswaldo Cruz. Laboratório de Biotecnologia Aplicada à Saúde. Porto Velho, RO, Brazil. / Universidade Federal de Rondônia. Programa de Pós-Graduação em Biologia Experimental. Porto Velho, RO, Brazil. / Programa de Pós-Graduação em Biodiversidade e Biotecnologia da Amazônia Legal. Porto Velho, RO, Brazil.During Leishmania infection, host immune response is important to prevent the growth/survival of intracellular amastigotes. In this study, we evaluated in vitro and in vivo whether or not during Leishmania amazonensis infection, pentavalent antimonial treatment/therapy could be more effective under TNF-α inhibition. Both L. amazonensis-infected macrophages (in vitro model) and mice (in vivo model) were treated with a nuclear factor-kB (NF-kB) inhibitor and with Glucantime®, alone and in combined administrations. The in vitro amastigote counts, cytokines and nitrites' production were assessed after 48 h incubation with the drugs. Paw lesion sizes and amastigote counts were also evaluated in vivo. Quantification of IL-1β from the infected tissue was performed. In vitro results show that when infected macrophages were incubated with QNZ + Glucantime®, a greater clearance was observed for the amastigotes' growth and this was related to greater nitrite production compared to the group that was only infected. In vivo results show that mice that received the combined treatment had their paw lesion sizes and amastigote nests inside the macrophages greatly diminished, correlating with increased IL-1β levels.Leishmania amazonensisAntimonial therapyTNF-α inhibitionIL-1βNitric oxideImmune responseinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-82991https://www.arca.fiocruz.br/bitstream/icict/12621/1/license.txt5a560609d32a3863062d77ff32785d58MD51ORIGINALThe pentavalent antimonial therapy.pdfThe pentavalent antimonial therapy.pdfapplication/pdf793426https://www.arca.fiocruz.br/bitstream/icict/12621/2/The%20pentavalent%20antimonial%20therapy.pdfa3dd8cd4d33d44c6a78681e2f4032f28MD52TEXTThe pentavalent antimonial therapy.pdf.txtThe pentavalent antimonial therapy.pdf.txtExtracted texttext/plain29638https://www.arca.fiocruz.br/bitstream/icict/12621/3/The%20pentavalent%20antimonial%20therapy.pdf.txt8c0548716d86653fec05970c5a1db36fMD53icict/126212021-02-10 19:38:01.329oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352021-02-10T22:38:01Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.pt_BR.fl_str_mv The pentavalent antimonial therapy against experimental Leishmania amazonensis infection is more effective under the inhibition of the NF-kB pathway
title The pentavalent antimonial therapy against experimental Leishmania amazonensis infection is more effective under the inhibition of the NF-kB pathway
spellingShingle The pentavalent antimonial therapy against experimental Leishmania amazonensis infection is more effective under the inhibition of the NF-kB pathway
Macedo, Sharon Rose Aragão
Leishmania amazonensis
Antimonial therapy
TNF-α inhibition
IL-1β
Nitric oxide
Immune response
title_short The pentavalent antimonial therapy against experimental Leishmania amazonensis infection is more effective under the inhibition of the NF-kB pathway
title_full The pentavalent antimonial therapy against experimental Leishmania amazonensis infection is more effective under the inhibition of the NF-kB pathway
title_fullStr The pentavalent antimonial therapy against experimental Leishmania amazonensis infection is more effective under the inhibition of the NF-kB pathway
title_full_unstemmed The pentavalent antimonial therapy against experimental Leishmania amazonensis infection is more effective under the inhibition of the NF-kB pathway
title_sort The pentavalent antimonial therapy against experimental Leishmania amazonensis infection is more effective under the inhibition of the NF-kB pathway
author Macedo, Sharon Rose Aragão
author_facet Macedo, Sharon Rose Aragão
Nicolete, Larissa Deadame de Figueiredo
Ferreira, Amália dos Santos
Barros, Neuza Biguinati de
Nicolete, Roberto
author_role author
author2 Nicolete, Larissa Deadame de Figueiredo
Ferreira, Amália dos Santos
Barros, Neuza Biguinati de
Nicolete, Roberto
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Macedo, Sharon Rose Aragão
Nicolete, Larissa Deadame de Figueiredo
Ferreira, Amália dos Santos
Barros, Neuza Biguinati de
Nicolete, Roberto
dc.subject.en.pt_BR.fl_str_mv Leishmania amazonensis
Antimonial therapy
TNF-α inhibition
IL-1β
Nitric oxide
Immune response
topic Leishmania amazonensis
Antimonial therapy
TNF-α inhibition
IL-1β
Nitric oxide
Immune response
description 2016-11-30
publishDate 2015
dc.date.issued.fl_str_mv 2015
dc.date.accessioned.fl_str_mv 2016-01-26T14:37:54Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv NICOLETE, R. et al. The pentavalent antimonial therapy against experimental Leishmania amazonensis infection is more effective under the inhibition of the NF-κB pathway. International Immunopharmacology (Print), v. 28, p. 554-559, 2015.
dc.identifier.uri.fl_str_mv https://www.arca.fiocruz.br/handle/icict/12621
dc.identifier.doi.none.fl_str_mv 10.1016/j.intimp.2015.07.020
identifier_str_mv NICOLETE, R. et al. The pentavalent antimonial therapy against experimental Leishmania amazonensis infection is more effective under the inhibition of the NF-κB pathway. International Immunopharmacology (Print), v. 28, p. 554-559, 2015.
10.1016/j.intimp.2015.07.020
url https://www.arca.fiocruz.br/handle/icict/12621
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv ELSEVIER
publisher.none.fl_str_mv ELSEVIER
dc.source.none.fl_str_mv reponame:Repositório Institucional da FIOCRUZ (ARCA)
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Repositório Institucional da FIOCRUZ (ARCA)
collection Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv https://www.arca.fiocruz.br/bitstream/icict/12621/1/license.txt
https://www.arca.fiocruz.br/bitstream/icict/12621/2/The%20pentavalent%20antimonial%20therapy.pdf
https://www.arca.fiocruz.br/bitstream/icict/12621/3/The%20pentavalent%20antimonial%20therapy.pdf.txt
bitstream.checksum.fl_str_mv 5a560609d32a3863062d77ff32785d58
a3dd8cd4d33d44c6a78681e2f4032f28
8c0548716d86653fec05970c5a1db36f
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv repositorio.arca@fiocruz.br
_version_ 1798325084115435520

Registros relacionados